Foldax announced publication of the first clinical results for its TRIA™ biopolymer heart valve - the first polymer valve...
Read more
Foldax® announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve. The...
Read more
Foldax announced the successful first-in-human use of its biopolymer Tria™ heart valve in surgically replacing a diseased mitral valve....
Read more
Foldax is looking to reinvent every aspect of the heart valve—from material, to design, to manufacturing. Foldax is working...
Read more
Foldax has announced the publication of a research paper in Advanced NanoBiomed Research that concluded that its LifePolymer biopolymer...
Read more
Foldax®, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to...
Read more
The Salt Lake City, UT-based company won FDA approval to expand a clinical study of the Tria surgical aortic...
Read more
Foldax announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the U.S. clinical study...
Read more
Foldax® announced that it has been selected as Company of the Year among 10 cardiovascular device company finalists by...
Read more
Foldax® announced key additions to its Scientific and Medical Advisory Boards who will contribute to the continued development of...
Read more